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ABSTRACT Our current understanding of how low antibiotic concentrations shape the
evolution of contemporary b-lactamases is limited. Using the widespread carbapenemase
OXA-48, we tested the long-standing hypothesis that selective compartments with low
antibiotic concentrations cause standing genetic diversity that could act as a gateway to
developing clinical resistance. Here, we subjected Escherichia coli expressing blaOXA-48, on a
clinical plasmid, to experimental evolution at sub-MICs of ceftazidime. We identified and
characterized seven single variants of OXA-48. Susceptibility profiles and dose-response
curves showed that they increased resistance only marginally. However, in competition
experiments at sub-MICs of ceftazidime, they demonstrated strong selectable fitness bene-
fits. Increased resistance was also reflected in elevated catalytic efficiencies toward ceftazi-
dime. These changes are likely caused by enhanced flexibility of the X- and b5-b6 loops
and fine-tuning of preexisting active site residues. In conclusion, low-level concentrations of
b-lactams can drive the evolution of b-lactamases through cryptic phenotypes which may
act as stepping-stones toward clinical resistance.
IMPORTANCE Very low antibiotic concentrations have been shown to drive the evolu-
tion of antimicrobial resistance. While substantial progress has been made to under-
stand the driving role of low concentrations during resistance development for dif-
ferent antimicrobial classes, the importance of b-lactams, the most commonly used
antibiotics, is still poorly studied. Here, we shed light on the evolutionary impact of
low b-lactam concentrations on the widespread b-lactamase OXA-48. Our data indi-
cate that the exposure to b-lactams at very low concentrations enhances b-lacta-
mase diversity and drives the evolution of b-lactamases by significantly influencing
their substrate specificity. Thus, in contrast to high concentrations, low levels of
these drugs may substantially contribute to the diversification and divergent evolu-
tion of these enzymes, providing a standing genetic diversity that can be selected
and mobilized when antibiotic pressure increases.
KEYWORDS OXA-48, ceftazidime, resistance development, cryptic evolution,
Escherichia coli, carbapenemase, carbapenem, sub-MIC, structural flexibility, catalytic
efficiency
Since the discovery of the first b-lactam, penicillin, this antimicrobial class has diversifiedinto a broad range of agents, and it remains the most widely used class of antimicrobials
worldwide (1). The extensive use of these agents has inevitably led to the selection of
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multiple resistance mechanisms where the expression of b-lactamase enzymes plays a
major role, particularly in Gram-negative bacteria (2). Consequently, b-lactamases are argu-
ably among the most-studied enzymes worldwide. Considerable progress has been made in
understanding their molecular epidemiology and biochemical properties (3, 4). The evolu-
tionary forces driving the diversification of these enzymes are, however, poorly understood.
Already, more than 20 years ago, it was proposed that suboptimal antibiotic concentrations
within the host fuel the evolution of b-lactamases, altering their substrate profiles (5–8). This
“compartment hypothesis” was later supported by a series of studies unequivocally demon-
strating that selection for antibiotic resistance determinants can occur at very low antibiotic
concentrations (9–11). These low concentrations are thus widening the window in which
selection can take place (12). Despite their clinical significance, few studies have investigated
the effects of sub-MICs of b-lactams on the evolution and selection of contemporary, glob-
ally circulating b-lactamases (5, 13, 14).
Within the last decade, OXA-48 has become one of the most widespread serine
b-lactamases. This Ambler class D b-lactamase confers resistance toward penicillins
and decreases susceptibility to our last-resort drugs, the carbapenems. However, it is a
poor hydrolyzer of extended-spectrum cephalosporins, including ceftazidime (15–17).
Despite that, naturally occurring OXA-48-like variants have been identified exhibiting
increased ceftazidime activity but antagonistic pleiotropy toward penicillins and carbape-
nems (e.g., OXA-163, OXA-247, and OXA-405) (18–20). Ceftazidime resistance development
in these variants was mostly due to single amino acid changes and a shortened b5-b6 loop
(4, 18–21). We previously showed that exposure to increasing concentrations of ceftazidime
can select for this latent ceftazidimase function of OXA-48 in the laboratory (17).
To test the long-standing hypothesis, that b-lactams at sub-MICs can drive the evo-
lution of these enzymes, we subjected Escherichia coli MG1655 expressing OXA-48 to
concentrations of ceftazidime below the MIC (0.25 MIC). Over the course of 300 gen-
erations, we identified seven single variants of OXA-48 (L67F, P68S, F72L, F156C/V,
L158P, and G160C). Their ceftazidime MICs were indistinguishable or only marginally
increased compared to wild-type OXA-48. However, when expressed at sub-MICs of
ceftazidime, all allele variants conferred strong fitness benefits. Measuring dose-
response curves (50% inhibitory concentration [IC50]) and enzyme kinetics revealed fur-
ther that (i) all genotypes decreased ceftazidime susceptibility significantly and (ii) all
enzyme variants exhibited increased catalytic efficiencies against ceftazidime.
Molecular dynamics (MD) simulations of P68S, F72L, and L158P showed elevated flexi-
bility of both the X (D143 to I164) and b5-b6 (T213 to K218) loops likely to aid hydro-
lysis of the bulkier ceftazidime by increasing active site accessibility. Structural investi-
gations of L67F also revealed a novel binding pocket outside of the active site where
the b5-b6 loop was involved in stabilizing the binding of the hydrolyzed ceftazidime
molecule. Worryingly, double mutants, such as F72I/G131S (OXA-D320, GenBank acces-
sion no. KJ620465) and N146S/L158P (OXA-D319, GenBank accession no. KJ620462),
were recently identified in environmental samples (22, 23), underlining the importance
and evolutionary power of environments with low selective pressure.
RESULTS
Sub-MICs of ceftazidime select for high-level resistance. Here, we wanted to
study the evolvability of the carbapenemase OXA-48 under sub-MICs of the cephalosporin
ceftazidime. OXA-48 does not hydrolyze ceftazidime efficiently (19). However, we recently
showed that the exposure to increasing concentrations of ceftazidime can select for OXA-48
variants with elevated activity toward ceftazidime (17). We used the previously constructed
E. coli MG1655 (Table S1, MP13-06) (17) carrying a globally disseminated IncL plasmid with
blaOXA-48 as the only antibiotic resistance gene. MP13-06 was evolved without selection pres-
sure and at one quarter of the ceftazidime MIC (0.06mg/liter), resulting in the populations 1
to 3 (Pop1 to 3) and 4 to 6 (Pop4 to 6), respectively (Fig. 1a).
To elucidate the effect of ceftazidime, we measured dose-response curves of the
whole evolved populations and calculated the ceftazidime concentrations inhibiting
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FIG 1 Population-level effects of sub-MIC ceftazidime exposure. (a) Experimental design. (b) IC50 fold change for populations evolved
without (gray) and under sub-MIC ceftazidime conditions (violet), relative to wild-type OXA-48. Bands represent the standard deviation
around the geometric mean. (c) The top section shows the fraction of clones able to grow on ceftazidime, 1mg/liter (.2-fold MIC);
the bottom section displays MIC fold change distributions of preselected clones. Box plots represent quartiles and the median of the
distributions.
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50% of cell growth (IC50). In Pop1 to 3, evolution without selection pressure did not
result in altered ceftazidime susceptibility (Fig. 1b). In contrast, under ceftazidime
selection (Pop4 to 6), susceptibility decreased on average 16-fold already after 50 gen-
erations (Fig. 1b). We observed that, during the course of experimental evolution, the
susceptibilities of Pop4 to 6 shifted toward lower ceftazidime resistance (Fig. 1b).
From the evolved populations, we measured the fraction of clones exhibiting a clin-
ically significant MIC change (.2-fold) by nonselective and selective plating on 1mg/li-
ter ceftazidime. No clones were identified during selection-free evolution above the
detection limit (1027 of the population). Under sub-MIC conditions, we found a signifi-
cant fraction of the populations to be able to grow on ceftazidime containing plates
(Fig. 1c). While this fraction was stably maintained in Pop4, we found that Pop5 and
Pop6 showed a significant reduction over time (Pearson correlation, P=0.54, P=0.01,
P=0.03).
To determine the MIC distribution of clones with increased MICs, we selected
approximately 50 colonies every 50th generation from the selective plates and tested
their susceptibility to ceftazidime (Fig. 1c). All preselected clones displayed a MIC
increase ranging from 2- to 128-fold. For Pop 4 to 6, we found that on average, 11%,
28%, and 34% of the tested colonies exhibited MIC values above the clinical resistance
breakpoint of 4mg/liter, respectively (EUCAST breakpoint table v. 10.0). These results
are consistent with recent reports demonstrating that low-level concentrations of anti-
biotics facilitate the selection of high-level resistance (9, 11).
Sub-MIC evolution selects for beneficial single point mutations in blaOXA-48. To
understand the effect of sub-MIC exposure on OXA-48, we sequenced the blaOXA-48
gene of approximately 50 clones after 50 and 300 generations, which were preselected
on agar plates containing 1mg/liter ceftazidime. In total, seven single variants of OXA-
48 were identified: L67F, P68S, F72L, F156C, F156V, L158P, and G160C. The relative fre-
quency of these variants varied among populations and generations (Fig. 2a).
Interestingly, double mutants with similar (F72I/G131S) or identical (N146S/L158P)
amino acid changes have been already reported in environmental samples (23). To elu-
cidate the effect of these second mutations, we constructed the OXA-48 double
mutants F72L/G131S (instead of F72I) and N146S/L158P and included them in the fol-
lowing characterization.
To isolate the effects of OXA-48 on antimicrobial susceptibility, we subcloned all al-
lele variants into a high copy number vector (pCR-Blunt II-TOPO) and expressed them
in E. coli TOP10 (Table 1). As previously shown (17), the expression of OXA-48 resulted
in up to 32- and 64-fold increased MIC toward penicillins and carbapenems (except for
doripenem), respectively. While wild-type OXA-48 expression did not increase the MIC
against cephalosporins (,2-fold), we found that P68S, F72L, L158P, and N146S/L158P
resulted in 4- to 16-fold increased MIC against ceftazidime. Interestingly, the expres-
sion of all other alleles (L67F, F156C/V, G160C, F72L/G131S) did not increase the cefta-
zidime MIC significantly (i.e., not more than 2-fold compared to wild-type OXA-48). In
addition, none of the alleles showed a significant effect on cephalosporins other than
ceftazidime (Table 1). In contrast, the susceptibility to carbapenems and penicillins was
increased by 2- to $64-fold for all the variants. The expression of F156C and G160C did
not increase the MIC to any b-lactam. In clinical strains, blaOXA-48 is frequently located
on IncL plasmids, which are typically present in low copy numbers (24). To mimic this
situation, we subcloned all OXA-48 alleles into a low copy number vector (p15A origin,
here called pUN), expressed these in E. coli MG1655, and repeated the ceftazidime MIC
measurements. Within this more realistic genetic architecture, only F156V increased
the ceftazidime MIC by more than 2-fold (Table 2).
Clinically insignificant or marginal changes in MICs have been reported to still con-
fer high fitness benefits in the presence of low-level selection (5). To address this, we
first increased the resolution of the susceptibility testing by measuring the dose-
response curves in the low copy number vector. Calculating their corresponding IC50
values, we found that all variants conferred marginal but significant decreases in
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FIG 2 Phenotypic and structural investigation of OXA-48 allele variants. (a) Relative genotype frequencies of blaOXA-48 variants within Pop4
to 6, at 50 and 300 generations. (b) Relative growth advantage of OXA-48 variants expressed at sub-MICs of ceftazidime versus their
(Continued on next page)
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ceftazidime susceptibility (Fig. 2b and Table 2; analysis of variance [ANOVA], df = 10,
P, 0.0001, followed by a Dunnett post hoc test with OXA-48 as the control group).
Second, we performed head-to-head competitions between isogenic E. coli MG1655
strains (only differing in DmalF) to test the fitness effect of OXA-48 variants in the absence
and presence of sub-MIC ceftazidime. To exclude an effect of the malF deletion on the bac-
terial fitness, we initially competed the strains both carrying the pUN vector encoding wild-
type blaOXA-48 (MP08-61 and MP14-24). No significant change in bacterial fitness was
observed in either condition (Welch t-test, P=0.24 and P=0.48), ruling out a detectable
effect of the malF deletion. Next, we expressed all OXA-48 variants in MP14-23 and sub-
jected those to competitions against MP08-61. Without ceftazidime, no difference in fitness
was observed between variants and wild type (Fig. 3a; ANOVA, not assuming equal varian-
ces, df=7, P=0.33). However, at sub-MIC ceftazidime, all allele variants showed strong signif-
icant growth benefits (Fig. 2b and 3a; ANOVA, not assuming equal variances, df=7,
P=0.0003, followed by a Dunnett post hoc test with OXA-48 as the control group).
Two mutational targets identified in our study (F72L and L158P) were recently isolated
from the environment, in combination with a second amino acid substitution (23). We
aimed to elucidate the effect of G131S and N146S in combination with F72L and L158P,
respectively. To do so, we competed F72L and L158P against the double mutants F72L/
G131S and N146S/L158P, respectively. No significant change in fitness was detectable in the
absence of selection pressure (Fig. 3b; Welch t-test, P=0.24 and 0.62 for F72L/G131S and
N146S/L158P, respectively). At sub-MIC ceftazidime, our data suggest no positive selection
for the double mutants (Fig. 3b; paired Welch t-test between conditions, P=0.038 and 0.59
for F72L/G131S and N146S/L158P, respectively). Thus, the role of these second mutations
remains unclear.
Mutations within blaOXA-48 alter enzymatic properties. In this study, sub-MIC levels
of ceftazidime were shown to select for OXA-48 variants conferring high bacterial fitness
advantages despite only cryptic resistance phenotypes, suggesting that, in the clinical setting,
these genetic changes are likely to remain undetected. To further our understanding of how
these cryptic changes influence the enzymatic properties of OXA-48, we expressed the
enzymes without their leader sequence in E. coli BL21 AI (Table S1). After enzyme purification,
FIG 2 Legend (Continued)
ceftazidime IC50. Despite marginal changes in their ceftazidime susceptibility (IC50 increased by 2- to 4-fold), the expression of these alleles
displays large fitness benefits at sub-MIC ceftazidime. Error bars represent the standard deviation. (c) Ribbon structure of OXA-48 including
the amino acid changes close to the active site. (d) Representative structures from molecular dynamics simulations of wild type, P68S,
F72L, and L158P performed with ceftazidime covalently bound to the active site S70. In short, S68 in P68S displays an H-bond with the
tyrosine in the conserved Y144GN motif of OXA-48. F72L lacks the aromatic stacking interaction between F72 and F156/W157. L158P
disrupts the H-bond network within the X-loop.



























Temocillin 16 256 64 64 64 16 16 64 16 16 32
Piperacillin-tazobactam 2 64 2 2 2 2 2 2 2 2 2
Amoxicillin-clavulanic acid 4 128 128 64 64 16 64 16 8 8 8
Ceftazidime 0.5 0.5 1 8 4 0.5 0.5 8 0.5 0.5 2
Ceftazidime-avibactam 0.25 0.25 0.5 0.25 0.5 0.5 0.5 0.5 0.5 0.25 0.5
Cefuroxime 16 16 8 16 8 8 8 8 8 16 8
Cefepime 0.06 0.12 0.06 0.12 0.12 0.06 0.06 0.25 0.06 0.06 0.12
Cefotaxime 0.12 0.25 0.12 0.12 0.12 0.12 0.12 0.25 0.12 0.25 0.12
Meropenem 0.03 0.25 0.12 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Imipenem 0.25 1 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.5
Ertapenem 0.015 1 0.12 0.03 0.03 0.015 0.015 0.06 0.015 0.015 0.015
Doripenem 0.03 0.03 0.03 0.03 0.06 0.03 0.03 0.06 0.03 0.06 0.06
aTazobactam fixed at 4mg/ml; clavulanic acid fixed at 2mg/ml; avibactam fixed at 4mg/ml.
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protein masses were verified using electrospray ionization mass spectrometry (ESI-MS). The
molecular weight of five out of seven variants corresponded to their calculated monoisotopic
masses (Table 3). For F156C and G160C, we observed an increase in molecular weight by
76Da, likely caused by the b-mercaptoethanol used during the purification process to mini-
mize aggregation.
We determined their catalytic efficiencies (kcat/Km) toward a panel of b-lactams and
found that they were in line with the antimicrobial susceptibility data. Toward ceftazidime,
kcat/Km values were increased by 2- to 31-fold (Table 3) for all variants compared to wild-type
OXA-48. Moreover, all variants exhibited strongly reduced activity (up to several magnitudes)
against penicillins (ampicillin and piperacillin) as well as toward carbapenems (meropenem
and imipenem). To test for cross-activity against 4th-generation cephalosporins, we determined
FIG 3 Head-to-head competitions. (a) E. coli MG1655 mal1 competed with MG1655 DmalF expressing
wild-type and allele variants of OXA-48, respectively, without (gray) and at sub-MICs (violet) of
ceftazidime. While expression without selection pressure was neutral for all alleles, at sub-MICs, all allele
variants showed fitness benefits over the wild-type allele. (b) E. coli MG1655 mal1 expressing F72L versus
DmalF F72L/G131S and mal1 L158P versus DmalF N146S/L158P. G131S and N146S did not improve
bacterial fitness at sub-MIC ceftazidime. The dots represent biological replicates, and significantly different
averages compared to OXA-48 in the presence of ceftazidime (0.06mg/liter) are marked with * (P , 0.05),
** (P, 0.01), and *** (P, 0.001).











kcat/Km (mM21 s21) for:c
Ampicillin Piperacillin Ceftazidime Cefepimef Imipenem Meropenem
Wild type 28,186.3 28,186.5 55.9 5.56 103 2.26 103 3.4 1021 1.20 1021 1.05 102 4.58 101
L67F 28,220.3 28,220.4 51.4 4.66 102 7.80 100 9.4 1021 1.68 1022 6.38 100 7.81 1021
P68S 28,176.3 28,176.3 48.3 1.80 102 1.48 101 1.6 100 9.12 1022 3.56 100 3.20 100
F72L 28,152.3 28,151.5 49.2 1.44 102 1.35 101 1.1 101 8.81 1023 3.38 100 4.47 100
F156Cd 28,142.3 28,218.3 50.7 2.24 102 9.39 100 1.5 100 2.42 1022 8.17 1022 6.54 1022
F156V 28,138.3 28,138.5 50.2 1.18 102 9.03 100 1.5 100 3.35 1022 2.85 100 6.10 1021
L158P 28,170.3 28,170.5 50.3 2.37 102 2.69 101 6.7 1021 ND 1.38 100 4.56 1021
G160Cd 28,232.3 28,308.3 48.4 2.24 102 1.40 101 3.6 100 1.27 1021 4.36 100 6.52 100
F72L/G131Se 28,182.3 28,182.0 45.2 1.46 102 3.07 101 5.9 1021 1.27 1021 2.03 100 8.94 100
N146S/
L158Pe
28,143.3 28,142.0 50.7 2.05 102 2.87 101 6.9 101 ND 3.02 1021 5.76 1021
aMonoisotopic mass after TEV cleavage.
bMeasured as thermostability.
cMichaelis-Menten kinetics could not be saturated for most of the variants; therefore, only kcat/Km values were reported.
dPurified in the presence of b-mercaptoethanol to minimize aggregation.
eSecond mutations (G131S and N146S) described in environmental samples.
fND, no activity detected.
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the catalytic efficiencies against cefepime. Also, here, we found that the OXA-48 variants
tended to display kcat/Km values several magnitudes lower than the wild-type OXA-48
(Table 3).
Functional mutations within serine b-lactamases have frequently been described to
decrease the thermostability (17, 25, 26). Indeed, compared to wild-type OXA-48, all
single amino acid changes were deleterious with respect to thermostability, which
decreased by 4.5 to 7.6°C (Table 3). F72L/G131S exhibited the lowest melting tempera-
ture, with a decrease of 10.7°C. Generally, we found the following order for the thermal
stability OXA-48. L67F . F156C = N146S/L158P . L158P = F156V . F72L . G160C =
P68S. F72L/G131S.
P68S, F72L, and L158P increase the loop flexibility within OXA-48. Single amino
acid changes in OXA-48 were responsible for increased catalytic activity against ceftazi-
dime. To understand the underlying structural changes allowing these OXA-48 variants
to hydrolyze ceftazidime more efficiently, we first mapped all amino acid changes onto
the structure of OXA-48, showing that they clustered around the a3-helix (L67F, P68S,
and F72L) and the X-loop (F156C, F156V, L158P, and G160C) (Fig. 2c). Second, multiple
independent MD simulations were performed on a subset of variants (P68S, F72L, and
L158P) with covalently bound ceftazidime in their active site. Our previous study
showed that an amino acid change at position 68 (P68A) decreases ceftazidime suscep-
tibility in OXA-48 (17). Additionally, positions 72 and 158 were selected due to amino
acid changes recently identified in environmental samples (F72I and L158P). Changes
in enzyme flexibility were analyzed by calculating root mean square fluctuations
(RMSF) for the backbone atoms in the X- and b5-b6 loops and compared to wild-type
OXA-48 and the ceftazidimase OXA-163 (only X-loop, due to the shortened b5-b6
loop).
For the X-loop, P68S displayed very similar RMSF values relative to OXA-48; how-
ever, F72L and L158P showed increased flexibility in this region, displaying even higher
RMSF values than OXA-163 (Fig. 4a). Notably, the L158P substitution increased fluctua-
tions specifically for residues N152 to S155. V153 demonstrated the largest overall shift
in RMSF values, with an increase of 0.7 Å compared to OXA-48. For the b5-b6 loop, all
variants exhibited an increase in fluctuations, especially for the residues T213 to E216
(Fig. 4b).
Possible changes in intramolecular interactions due to the amino acid changes
P68S, F72L, and L158P were also studied from MD simulations. For P68S, an H-bond
was observed between the hydroxyl groups of S68 and Y144 (Fig. 2d). However, no
other apparent structural changes near the active site were directly observed, and
therefore, the effect of P68S on the dynamic nature remains elusive.
In wild-type OXA-48, W157 in the X-loop stacks with both F72 and F156 (Fig. 2d).
Consequently, the lack of this interaction in F72L likely increases the flexibility of W157,
which is reflected by a 0.2-Å increase in calculated RMSF (Fig. 4a). Furthermore, the
wild-type X-loop displays an organized H-bond network, which extends to R128 and
R214 on either side (Fig. 2d). We found that L158P is likely affecting this network by
disrupting the interactions with S155 and D159 (Fig. 2d). Consequently, the salt bridge
between R128 and D154 was found to be weakened, as its presence was reduced from
87% to 43% of the simulation time. The loss of the backbone H-bond between L158
and S155, in the proline variant (L158P), has a knock-on effect on the rest of the loop,
making it more flexible and likely to better accommodate bulkier b-lactam substrates
such as ceftazidime.
Aside from flexibility and changes in amino acid interactions, possible further
effects on the overall enzyme dynamics were inspected by performing principal com-
ponent (PC) analysis on the combined MD trajectories (using the Ca-atom positions).
The overall sampling of conformational space is highly similar for OXA-48 and the
three variants. There are no specific large conformational changes or coordinated loop
movements induced by the mutations. Some differences between variants and wild-
type OXA-48 were observed particularly for PCs that primarily involve movement of
b-Lactamase Evolution under Sub-MIC Conditions
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loops, including those surrounding the active site, further indicating that the mutations
introduce small changes in loop dynamics (Fig. 4c and d).
Cryptic binding pocket for ceftazidime in OXA-48. To investigate substrate binding,
all OXA-48 variants were crystalized and soaked with ceftazidime. We were able to solve the
crystal structure of L67F to 1.9Å with four chains (A to D) in the asymmetric unit (space
group P212121), which were arranged into two dimers (chains A/C and B/D). Chain C and D
carried a hydrolyzed ceftazidime molecule approximately 9Å away from the active site S70.
The R1-group of ceftazidime including the dihydrothiazine ring demonstrated clear electron
density (2Fo-Fc); however, no electron density was observed for the R2-ring (Fig. 5, top).
We first investigated the binding of ceftazidime to the L67F variant. Here, we found
that Q98, R100, D101, W105, V120, P121, Q124, L158, T213, and R214 formed a cryptic
FIG 4 Differences in dynamics between wild-type OXA-48 and variants P68S, F72L, and L158P (as well as OXA-163). Loop flexibility as measured by
backbone root mean square fluctuations (RMSFs) from molecular dynamics simulations for residues in the X-loop (a) and in the b5-b6 loop (b). Principal
component (PC) analysis of the Ca atoms from molecular dynamics simulations of OXA-48 and the P68S, F72L, and L158P variants, with PC1 (c, top) and
PC5 (d, top) illustrated on ribbon structures using arrows indicating the direction of the eigenvectors and the magnitude of the corresponding eigenvalue
(for clarity, arrows are only shown for atoms with eigenvalues of.2.5 Å). Normalized histograms (using 200 bins per enzyme) for PC1 (c, bottom) and PC5
(d, bottom) indicate differences of the range of the PC sampled in different variants.
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pocket outside the active side and that these residues were involved in stabilizing the
hydrolyzed ceftazidime molecule (Fig. 5, top). D101, Q124, T213, and R214 were found
to interact with ceftazidime via H-bonds. R214 was further involved in ionic interac-
tions with two of the carboxylic acid groups of hydrolyzed ceftazidime (Fig. 6).
Second, we investigated the active site architecture, including the first shell resi-
dues around S70. Chain A was therefore superimposed onto a wild-type structure of
OXA-48 (PDB no. 3HBR) (15). As expected, superimposition resulted in low root mean
square deviations of 0.21 Å. We found that K73 was carboxylated and that all first shell
residues nicely aligned with the wild-type structure (Fig. 5, middle).
FIG 5 Ceftazidime binding pocket (top panel), the 1st shell residues interacting with S70 (middle) and the
mutational site (bottom panel) of L67F (red) compared to the wild-type structure of OXA-48, shown in gray
(PDB no. 3HBR) (15). The crystal structure of L67F was solved to 1.9 Å and displayed hydrolyzed ceftazidime
;9Å away from the active site S70. (Top) Binding pocket of L67F without (left, chain C) and with (right, chain
A) ceftazidime compared to wild-type OXA-48. For ceftazidime, no 2Fo-Fc electron density was detected for the
R2 group. (Middle) Superimposition of the first shell residues of L67F (chain A) around the active site S70
compared the wild-type structure. (Bottom) Investigation of the mutational site, shown as the first shell
residues around L67F (both chain A and C), compared to wild-type OXA-48. Displacements of L158 (1 Å) and
I215 (2 Å) in the L67F structure are indicated with arrows. W221 was flipped 180° in the L67F structure.
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Third, we investigated the mutational site around L67F that is located “below” the
active site (Fig. 5, bottom). We found F66, P68, A69, W157, L158, R163, I215, and W221
to be directly interacting with amino acid position 67. In the L67F variant, both with
and without ceftazidime, L158 and I215 were shifted by 1 to 2 Å, respectively. In addi-
tion, we found W221 to be flipped by 180°. While in the wild-type structure, the W221
side chain forms a water-mediated H-bond to the backbone nitrogen of M237, in L67F,
W221 formed a H-bond to the main chain of F67 (Fig. 5).
DISCUSSION
Here, we asked if sub-MICs of the clinically relevant b-lactam ceftazidime could
affect the evolution of the contemporary, globally circulating carbapenemase OXA-48.
To test this, we evolved an OXA-48 producing E. coli strain in the presence of one-quarter of
its ceftazidime MIC. The identification of seven single variants of OXA-48, conferring only
marginal changes in susceptibility (Fig. 2b, Table 2), demonstrates that the exposure to sub-
MICs of ceftazidime drives the emergence of cryptic blaOXA-48 genetic diversity. Thus, our
data provide further support for the proposed compartment hypothesis (6, 8, 27, 28), where
low-grade selection promotes cryptic genetic variation that could act as stepping-stones to-
ward full clinical antibiotic resistance (29, 30). Notably, even though all seven single OXA-48
variants largely displayed, from a clinical microbiology perspective, negligible changes in cef-
tazidime susceptibility, competition experiments revealed strong beneficial fitness effects
(Fig. 2b). Taken together with earlier work, using reconstructed TEM-1 variants from clinical
samples (5), our data underscore the significance of divergent evolution and selection of
genetic variation imposed by sub-MICs of b-lactams.
To further our understanding of how the detected single amino changes affect the
structure-activity relationship of OXA-48, we first measured enzyme kinetics (Table 3).
The catalytic efficiency mirrored the observed changes in susceptibility toward b-lac-
tams at the cellular level and confirmed our previous findings that mutational changes
increasing ceftazidime activity come with a functional trade-off against penicillins and
carbapenems (17). However, decreased susceptibility might not only be reflected by
differences in the catalytic efficiency, as protein stability and translocation also affect
resistance levels toward b-lactams (31). Structurally, all amino acid changes clustered
FIG 6 Schematic representation of hydrolyzed ceftazidime in front of the active site of the OXA-48
variant L67F (based on PDB no. 7ASS). The ceftazidime side chains R1 and R2 are labeled and
marked. For R2, no electron density was observed and therefore no interactions were detected.
Hydrogen bonds from ceftazidime to D101, Q124, T213, and R214 are represented with dashed lines.
The ionic interactions with R214 are indicated with arrows.
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either around the active site S70 (L67F, P68S, F72L) or within the X-loop (F156C, F156V,
L158P, G160C; Fig. 2c).
In wild-type OXA-48, the X-loop interacts with the b5-b6 loop via a salt bridge
mediated by D159-R214 maintaining a closed conformation of the active site (15). MD
simulations performed on a subset of variants revealed that F72L and L158P weaken
the interaction between these loops, resulting in increased structural flexibility (Fig. 4).
We postulate that these changes aid the hydrolysis of bulkier substrates such as cefta-
zidime but result in decreased activity toward penicillins and carbapenems. Indeed,
mutations affecting the salt bridge are associated with reduced carbapenemase activ-
ity presumably due to increased loop flexibility (32).
In clinical OXA-48-like variants (e.g., OXA-163, OXA-247, and OXA-405) with increased cef-
tazidime activity, larger structural variations (deletions in combination with single point
mutations) within and around the b5-b6 loop have been reported (18–20). However, also,
single amino acid changes structurally close to the X- and b5-b6 loops have been shown
to slightly elevate the catalytic efficiency toward ceftazidime (E125Y in OXA-245 and V120L
in OXA-519) (33, 34). The significance of the X- and b5-b6 loops for the substrate profile is
not limited to OXA-48 (35, 36). These loops have been shown to impact substrate profiles for
other clinically relevant b-lactamases, including TEM and KPC (37–39). In addition, comparable
modes of action have been hypothesized for the OXA-10-like variants OXA-145 and OXA-147,
exhibiting L158D and W157L, respectively (according to OXA-48 numbering) (40–42).
We were able to solve the structure of the OXA-48 variant L67F, which showed the
reorientation of several active site residues such as L158 and I215 (Fig. 5, bottom).
Fine-tuning of active site residue conformations through more distal amino acid
changes is a common strategy in enzyme evolution (43) and may enable L67F to
increase activity toward ceftazidime. In addition, our structure revealed the presence
of a new cryptic binding site for ceftazidime, approximately 9 Å away from the active
site residue S70, involving interaction with the above-described b5-b6 loop (Fig. 5,
bottom) and R214, in particular. However, the mechanistic importance of this binding
and the pocket remains elusive, and more structural investigations are necessary.
Taken together, combining experimental evolution and structure-activity relationships
allowed us to identify and characterize single step mutations with cryptic resistance that yet
demonstrated significant fitness effects and structural changes. Our data show that to
understand the evolutionary potential of standing genetic diversity, susceptibilities charac-
terized solely by traditional MIC measurements provide too low resolution.
We acknowledge that our study is not without limitations, as despite strong fitness
effects, none of the variants went to fixation in any of the populations (Fig. 1c). We
argue that there can be at least two reasons for this. First, we have focused solely on
changes within OXA-48 and on a single drug. It is clear from our data that the evolu-
tion at sub-MICs also selected for other potential resistance mechanisms (e.g., efflux,
porins). These mechanisms could lead to potential widespread epistatic interactions
that would slow down any fixation process (9, 11, 44–46) and warrant further investiga-
tions, e.g., whole-genome sequencing. Second, it has been shown that b-lactamase
producers can detoxify their environment, allowing coexistence of genotypes with dif-
ferent susceptibilities, resulting in a stable equilibrium between resistant and suscepti-
ble clones (47).
Our work sheds light on the evolution of b-lactamases and their selection dynamics
toward altered substrate profiles. This is supported by recent studies reporting envi-
ronmental contamination of cephalosporins at concentrations similar to those applied
here (48, 49). Moreover, OXA-48 variants, with the same or similar amino acid changes
as identified and characterized here, have been reported in environmental samples
(22, 50). We speculate that the identified mutations are only first step mutations to-
ward full clinical ceftazidime resistance mediated by OXA-48. However, more studies
are needed to fully understand the complete fitness landscape of OXA-48 and other
carbapenemases.
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Media, chemicals, and strains. Mueller-Hinton (MH) agar and broth were purchased from Thermo
Fisher Scientific (East Grinstead, UK). Luria-Bertani (LB) broth, LB agar, yeast extract, agar, terrific broth,
ampicillin, amoxicillin, cefepime, ceftazidime, chloramphenicol, imipenem, meropenem, piperacillin,
2,3,5 tri-phenyl tetrazolium, sodium chloride, and maltose were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Tryptone was obtained from Oxoid (Hampshire, UK). All strains used and constructed within
this study are listed in Table S1.
Sub-MIC evolution. MP13-06, previously constructed and tested (17), was evolved by serial passag-
ing without selection pressure and at 0.25 MIC (0.06mg/liter) of ceftazidime for 300 generations. In
short, bacterial suspensions were grown at 37°C and 700 rpm on a plate shaker (Edmund Bühler,
Bodelshausen, Germany) in 1ml MH broth to full density and passaged every 12 h with a bottleneck of
1:100. The evolution was performed in triplicates.
Dose-response curves and susceptibility testing. Dose-response curves were obtained initially
and after every 50 generations for the whole evolved populations. Cultures were grown to full density and
diluted in 0.9% saline to 106 CFU/ml. Then, 384-well plates (VWR, Radnor, PA, USA) were inoculated with 105
CFU and increasing concentrations of ceftazidime ranging from 0 to 32mg/liter. Plates were statically incu-
bated for 20 h at 37°C. The optical density at 600nm (OD600) was measured with a microtiter plate reader
(BioTek Instruments, Winooski, VT, USA), and dose-response curves including IC50 values were calculated using
Prism 9.0 (GraphPad Software, San Diego, CA, USA). In this setup, the ceftazidime MIC was determined by
measuring the OD600 as the first well with an optical density comparable to the negative control.
For MIC measurements against b-lactams other than ceftazidime, in-house-designed and premade
Sensititre microtiter plates (TREK Diagnostic Systems/Thermo Fisher Scientific, East Grinstead, UK) were
loaded with 105 CFU. The plates were incubated statically for 20 h at 37°C. All susceptibility tests were
performed in at least two biological replicates.
Determination of clones with altered ceftazidime susceptibility. To determine clones exhibiting
decreased ceftazidime susceptibility, we plated 107 cells from every 50th generation on MH agar without
and with 1mg/liter ceftazidime. The plates were incubated for 24 h at 37°C. Clone frequencies were
determined as the ratio between colonies found on selective versus nonselective plates. About 50 prese-
lected colonies were subjected to susceptibility testing, as described above. For creating the boxplots, a
probability function was calculated based on the MIC per replicate. Since the MICs were determined in
2-fold steps, we generated smoother boxplots by creating 1,000 random measurements per generation.
We did so by drawing a random number between the log2 (MIC values) and log2 (MIC values) 1 1 a
1,000  f_mic, where f_mic is the fraction of the population. All calculations were done in Mathematica
11.0 (Wolfram Research, Champaign, IL, USA).
Strain construction. For functional resistance profiles, wild-type blaOXA-48 and allele variants were sub-
cloned into the high copy number vector pCR-blunt II-TOPO vector (Invitrogen, Carlsbad, CA, USA) and
expressed in E. coli TOP10 (Invitrogen). For wild-type TOPO-blaOXA-48, the construction has been described
previously (17). Point mutations were inserted by using the QuikChange II kit for site-directed mutagenesis
(Agilent Biosciences, Santa Clara, CA, USA), TOPO-blaOXA-48 as a template, and the respective primers
(Table S2). The double mutants TOPO-blaOXA-48-F72L/G131S and TOPO-blaOXA-48-N146S/L158P were created
by inverse PCR using Phusion polymerase (New England Biolabs, Ipswich, MA, USA) and TOPO-blaOXA-48-
F72L or TOPO-blaOXA-48-L158P as a template, respectively. PCR products were 59-phosphorylated with poly-
nucleotide kinase (Thermo Fisher Scientific, Waltham, MA, USA) and circularized using T4 DNA ligase
(Thermo Fisher Scientific). Transformants were selected on LB agar plates containing 50 or 100mg/liter
ampicillin. BlaOXA-48 was Sanger sequenced (BigDye 3.1 technology; Applied Biosystems, Foster City, CA,
USA) using M13 primers (Thermo Fisher Scientific) (Table S2).
For expression in a low copy number vector (pUN), we PCR-amplified a segment containing the
p15A origin of replication and the cat chloramphenicol resistance gene of the pACYC184 vector using
the primers cat-r and p15A46 (Table S2). To obtain the blaOXA-48 inserts, the pCR-blunt II-TOPO constructs
(see above) were used as templates. We amplified the blaOXA-48 genes by using the primers OXA-48-pro-
f, containing the constitutive artificial CP6 promoter (51), and preOXA-48B (Table S2) (52). These PCR
products were 59-phosphorylated with polynucleotide kinase (Thermo Fisher Scientific) and then blunt
ligated with the amplified vector backbone. The pUN-blaOXA-48 vector and the corresponding variants
were transformed into E. coli DH5a and plated on LB agar containing chloramphenicol (25mg/liter).
Genotypes of selected clones were confirmed by Sanger sequencing (BigDye 3.1 technology; Applied
Biosystems) using OXA-48-pro-f/preOXA-48B primers (Table S2) (52).
To measure bacterial fitness, E. coli MG1655 DmalF (MP14-23) was constructed as a competitor strain
by transducing the kanamycin resistance marker from the Keio strain JW3993 with P1-vir into E. coli
MG1655 as previously described (53, 54). The marker was then removed with the helper vector pCP20
(55). The competitor strain MP14-23 was then transformed with pUN-blaOXA-48 and the corresponding
variants (Table S1). Transformants were selected on LB plates containing 25mg/liter chloramphenicol.
For protein expression and purification, blaOXA-48 in the pDEST17 expression vector (Thermo Fisher
Scientific) was mutagenized using a QuikChange II site-directed mutagenesis kit as described above. E.
coli DH5a was transformed with the DNA constructs, and clones were selected on LB agar containing
100mg/liter ampicillin. The vectors were isolated using a plasmid maxi kit (Qiagen, Hilden, Germany)
and transformed into E. coli BL21 AI (Thermo Fisher Scientific). Point mutations were verified by Sanger
sequencing using T7 primers (Thermo Fisher Scientific) (Table S2).
Bacterial fitness: head-to-head competition. Strains were grown overnight in LB supplemented
with chloramphenicol (25mg/liter) at 37°C and 700 rpm on a plate shaker (Edmund Bühler). For each
competition, we coinoculated ;1 107 CFU/ml of each competitor in 1ml LB broth, supplemented
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either with chloramphenicol (25mg/liter) and ceftazidime (0.06mg/liter) or with chloramphenicol only.
Then, 96-deep-well plates (VWR) were incubated at 37°C and 700 rpm for 8 h. Each competition was per-
formed in three biological replicates. The initial and final CFU/ml for both competitors were determined
by differential plating on tetrazolium maltose agar (10 g/liter tryptone, 5 g/liter sodium chloride, 1 g/liter
yeast extract, 15 g/liter agar, 10 g/liter maltose, supplemented with 1ml 5% 2,3,5 tri-phenyl tetrazolium
chloride). Relative fitness (w) was determined according to equation 1, where mal1 and mal2 are,









The mal1 pUN-blaOXA-48 strain (MP08-61) was competed against DmalF strains carrying each of the pUN
vectors encoding wild-type blaOXA-48 or single variants (Table S1). Additionally, the mal
1 pUN-blaOXA-48-F72L
(MP08-67) and mal1 pUN-blaOXA-48-L158P (MP08-63) strains were used as competitors, respectively, against
strains DmalF pUN-blaOXA-48-F72L/G131S (MP14-32) and DmalF pUN-blaOXA-48-N146S/L158P (MP14-33), respec-
tively. Data analysis and graphical illustrations were performed in R 4.0.2 (56).
Recombinant enzyme expression and purification. Overexpression of OXA-48 and the corre-
sponding variants was done in terrific broth supplemented with 100mg/liter ampicillin. E. coli BL21 AI
carrying pDEST-17-blaOXA-48 and OXA-48 variants (Table S1) were grown at 37°C and 220 rpm to an opti-
cal density of 0.4 to 0.5. Protein expression was induced with 0.1% L-arabinose (Sigma-Aldrich).
Expression took place for 16 h at 15°C and 220 rpm. Harvested cells were sonicated, and recombinant
proteins were purified as described previously (17, 57). F156C and G160C were found to be insoluble. To
increase their solubility, 5mM b-mercaptoethanol was used during the sonication process.
Molecular mass verification. ESI-MS was performed on the purified enzymes as described previ-
ously (58). In short, a buffer exchange to 0.1% formic acid (Merck Millipore, Burlington, MA, USA) was performed
using centrifugal molecular cutoff filters (Merck Millipore; 10,000Da). The protein masses were determined using
an Orbitrap Fusion Lumos device (Thermo Fisher Scientific). Injection was performed using an EASY-nano LC
instrument (Thermo Fisher Scientific) with a 15-cm C18 EASY-spray column. Mass calculations were done using
BioPharma Finder 3.0 protein deconvolution software (Thermo Fisher Scientific, Massachusetts, USA).
Steady-state enzyme kinetics. Catalytic efficiencies (kcat/Km) for the recombinantly expressed
enzymes were determined under steady-state conditions for ampicillin (Dj = 2820 M21 cm21, 232 nm),
piperacillin (Dj = 2820 M21 cm21, 235 nm), ceftazidime (Dj = 29,000 M21 cm21, 260 nm), cefepime
(Dj = 210,000 M21 cm21, 260 nm), imipenem (Dj = 29,000 M21 cm21, 300 nm), and meropenem (Dj =
26,500 M21 cm21, 300 nm) by measuring the initial enzymatic reaction rate. The enzyme concentrations
are summarized in Table S3. All determinations were performed at least in duplicates at a final assay vol-
ume of 100 ml. UV-transparent 96-well plates (Corning, Kennebunk, ME, USA) were used. All test results
were obtained at 25°C and in 0.1 M phosphate buffer (pH 7.0) supplemented with 50mM NaHCO3
(Sigma-Aldrich). Calculations were performed using Prism 9.0 (GraphPad Software).
Thermostability.We determined the fluorescence-based protein thermostability for OXA-48 as described
previously (17). In short, the proteins were diluted in 50mM HEPES (VWR), pH 7.5 supplemented with 50mM
potassium sulfate (Honeywell, North Carolina, USA) to a final concentration of 0.2mg/ml protein and 5
SYPRO orange (Sigma-Aldrich). A temperature gradient of 25 to 70°C (heating rate, 1°C per min) was applied
using an MJ minicycler (Bio-Rad, Hercules, CA, USA). All experiments were performed in triplicates.
Molecular dynamics simulations. System setup was performed as described previously (59). In brief,
acyl-enzyme of OXA-48 with covalently bound ceftazidime was originally built using the structure of OXA-48
with imipenem (PDB no. 5QB4) (60) and replacing imipenem with ceftazidime (PDB no. 6Q5F) (17), which
ensured keeping the X-loop ordered (as found in the apoenzyme). For OXA-163, the same ceftazidime binding
pose was combined with apoenzyme crystal structure (PDB no. 4S2L) (61). All OXA-48 variants were modeled
using the mutagenesis tool in PyMOL, choosing the rotamer with the least steric clashes with surrounding
atoms. Enzymes were solvated in a 10-Å cubic box of TIP3P water with net charge neutralized by replacing
bulk water molecules with counterions. Parameters for nonstandard residues (carboxylated K73, ceftazidime
acyl-enzyme) have been published previously (59).
All systems were initially briefly minimized (1,000 steps of steepest descent followed by 1,000 steps of con-
jugate gradient), heated from 50 K to 300 K in 20 ps, and then simulated for 120ns in the NPT ensemble (sav-
ing a frame every 20 ps). Langevin dynamics were used with a collision frequency of 0.2 and a 2-fs time step;
all bonds involving hydrogens were constrained using the SHAKE algorithm. Periodic boundary conditions in
explicit solvent were applied in all simulations. Five independent simulations were run per enzyme variant (for
a total of 600ns per variant), and all calculations were done with the Amber18 program package (pmemd.
cuda) (62) using the ff14SB force field (63) for the protein and TIP3P for water (64, 65). All analyses were done
using CPPTRAJ from AmberTools (66). Root mean square fluctuation (RMSF) calculations were performed by
first calculating an average structure from the MD simulation, aligning the trajectory against the average struc-
ture excluding four residues from both the N- and C-terminal ends as well as the loop residues of interest
(G145-I164 for the X-loop and T213-I219 for the b5-b6-loop), and then calculating the RMSF for the corre-
sponding loop main chain heavy atoms (CA, C, N, O). The first 20ns were excluded from all analyses to allow
time for system equilibration. PC analysis was performed on Ca-atoms (excluding four residues from both the
N- and C-terminal ends), using all trajectories of OXA-48 and variants together (5 independent simulations of
120ns per variant).
Crystallization and structure determination. Crystals were grown in a 1-ml hanging drop containing
5mg/ml enzyme and mixed 1:1 with reservoir solution containing 0.1 M Tris, pH 9.0 (Sigma-Aldrich), and 28 to
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30% polyethylene glycol (PEG) mono ethylene ether 500 (Sigma-Aldrich) at 4°C. Crystals were harvested, cryo-
protected by adding 15% ethylene glycol (Sigma-Aldrich) to the reservoir solution, and then frozen in liquid
nitrogen.
Diffraction data were collected on BL14.1 BESSY II, Berlin, Germany, at 100 K, wavelength 0.9184 Å,
and the diffraction images were indexed and integrated using XDS (67). AIMLESS was used for scaling
(68). When scaling the final data set (Table S4), we aimed for high overall completeness and CC1/2 . 0.5
and a mean intensity above 1.0 in the outer resolution shell. The structure was solved by molecular
replacement with chain A of PDB no. 5QB4 (60) and the program PHENIX 1.12 (69). Parts of the model
were rebuilt using Coot (70). Figures were prepared using PyMOL 1.8 (Schrödinger, New York, NY, USA).
Ligand and protein interactions were calculated using Protein Contacts Atlas (71).
Data availability. Atom coordinates and structure factors for the OXA-48 variant L67F are available
in the protein data bank (PDB no. 7ASS). Underlying data are stored in an online repository at https://
github.com/GAMMAtri/Cryptic_b-lactamase_evolution.
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ACKNOWDLEGMENTS
We are very grateful to Linus Sandegren, Uppsala University, Sweden, and Francisco
Dionísio, University of Lisbon, Portugal, for providing strains. We thank Karina Xavier
(The Instituto Gulbenkian Ciência, Oeiras, Portugal) for providing the P1-vir phage.
Provision of beam time at BL14.1 at Bessy II, Berlin, Germany, is highly valued.
Hanna-Kirsti S. Leiros was supported by the Norwegian Research Council (273332/
2018). Bjarte A. Lund was supported by the Norwegian Research Council (262695 and
274858). Pål J. Johnsen was supported by Northern Norway Regional Health Authority,
UiT The Arctic University of Norway (Project SFP1292-16), and JPI-EC-AMR (project 271176/
H10). Viivi H. A. Hirvonen was supported by the UKRI Medical Research Council (MR/
N0137941/1). Marc W. van der Kamp is a BBSRC David Phillips fellow and thanks the
Biotechnology and Biological Sciences Research Council for funding (BB/M026280/1).
Simulations were performed using the computational facilities of the Advanced
Computing Research Centre, University of Bristol. We also extend our thanks to François
Pierre Alexandre Cléon, Vidar Sørum, Antal Martinecz, and AlexanderWessel for their help.
The publication charges for this article were funded by a grant from the publication
fund of UiT The Arctic University of Norway.
We declare no competing interests.
C.F., P.J.J., Ø.S., and H.-K.S.L. worked out the conceptional framework. C.F. conducted the
evolution. C.F. and J.A.G. performed microbiological testing. C.F., J.A.G., and K.H.
constructed strains. C.F. purified enzymes and measured kinetics. C.F. and H.-K.S.L. solved
the crystal structure. B.A.L. performed initial molecular dynamic simulations as a proof of
principle. V.H.A.H. and M.W.V.D.K. designed, performed, and analyzed the molecular
dynamic simulations. C.F. wrote themanuscript with contributions from all coauthors.
REFERENCES
1. Bush K, Bradford PA. 2016. b-lactams and b-lactamase inhibitors: an over-
view. Cold Spring Harb Perspect Med 6:a025247. https://doi.org/10.1101/
cshperspect.a025247.
2. Bush K. 2018. Past and present perspectives on b-lactamases. Antimicrob
Agents Chemother 62:e01076-18. https://doi.org/10.1128/AAC.01076-18.
3. Bonomo RA. 2017. b-Lactamases: a focus on current challenges. Cold Spring
Harb Perspect Med 7:a025239. https://doi.org/10.1101/cshperspect.a025239.
4. Pitout JDD, Peirano G, Kock MM, Strydom KA, Matsumura Y. 2019. The global
ascendency of OXA-48-type carbapenemases. ClinMicrobiol Rev 33:e00102-19.
5. Negri MC, Lipsitch M, Blazquez J, Levin BR, Baquero F. 2000. Concentra-
tion-dependent selection of small phenotypic differences in TEM b-lacta-
mase-mediated antibiotic resistance. Antimicrob Agents Chemother
44:2485–2491. https://doi.org/10.1128/aac.44.9.2485-2491.2000.
6. Baquero F, Negri MC, Morosini MI, Blazquez J. 1997. The antibiotic selec-
tive process: concentration-specific amplification of low-level resistant
populations. Ciba Found Symp 207:93–105. discussion 105–11. https://
doi.org/10.1002/9780470515358.ch7.
7. Baquero F. 2001. Low-level antibacterial resistance: a gateway to clinical
resistance. Drug Resist Updat 4:93–105. https://doi.org/10.1054/drup
.2001.0196.
8. Baquero F, Negri MC. 1997. Selective compartments for resistant microor-
ganisms in antibiotic gradients. Bioessays 19:731–736. https://doi.org/10
.1002/bies.950190814.
9. Gullberg E, Cao S, Berg OG, Ilback C, Sandegren L, Hughes D, Andersson
DI. 2011. Selection of resistant bacteria at very low antibiotic concentra-
tions. PLoS Pathog 7:e1002158. https://doi.org/10.1371/journal.ppat
.1002158.
Fröhlich et al.
March/April 2021 Volume 6 Issue 2 e00108-21 msphere.asm.org 16
 on A








10. Gullberg E, Albrecht LM, Karlsson C, Sandegren L, Andersson DI. 2014.
Selection of a multidrug resistance plasmid by sublethal levels of antibi-
otics and heavy metals. mBio 5:e01918-14. https://doi.org/10.1128/mBio
.01918-14.
11. Westhoff S, van Leeuwe TM, Qachach O, Zhang Z, van Wezel GP, Rozen
DE. 2017. The evolution of no-cost resistance at sub-MIC concentrations
of streptomycin in Streptomyces coelicolor. ISME J 11:1168–1178. https://
doi.org/10.1038/ismej.2016.194.
12. Baquero F, Coque TM. 2014. Widening the spaces of selection: evolution
along sublethal antimicrobial gradients. mBio 5:e02270. https://doi.org/
10.1128/mBio.02270-14.
13. Bagge N, Hentzer M, Andersen JB, Ciofu O, Givskov M, Hoiby N. 2004. Dy-
namics and spatial distribution of b-lactamase expression in Pseudomo-
nas aeruginosa biofilms. Antimicrob Agents Chemother 48:1168–1174.
https://doi.org/10.1128/aac.48.4.1168-1174.2004.
14. Murray AK, Zhang L, Yin X, Zhang T, Buckling A, Snape J, Gaze WH. 2018.
Novel insights into selection for antibiotic resistance in complex microbial
communities. mBio 9:e00969-18. https://doi.org/10.1128/mBio.00969-18.
15. Docquier JD, Calderone V, De Luca F, Benvenuti M, Giuliani F, Bellucci L,
Tafi A, Nordmann P, Botta M, Rossolini GM, Mangani S. 2009. Crystal struc-
ture of the OXA-48 b-lactamase reveals mechanistic diversity among
class D carbapenemases. Chem Biol 16:540–547. https://doi.org/10.1016/j
.chembiol.2009.04.010.
16. Poirel L, Heritier C, Tolun V, Nordmann P. 2004. Emergence of oxacillinase-
mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents
Chemother 48:15–22. https://doi.org/10.1128/aac.48.1.15-22.2004.
17. Fröhlich C, Sørum V, Thomassen AM, Johnsen PJ, Leiros HS, Samuelsen Ø.
2019. OXA-48-mediated ceftazidime-avibactam resistance is associated
with evolutionary trade-offs. mSphere 4:e00024-19. https://doi.org/10
.1128/mSphere.00024-19.
18. Gomez S, Pasteran F, Faccone D, Bettiol M, Veliz O, De Belder D, Rapoport
M, Gatti B, Petroni A, Corso A. 2013. Intrapatient emergence of OXA-247:
a novel carbapenemase found in a patient previously infected with OXA-
163-producing Klebsiella pneumoniae. Clin Microbiol Infect 19:E233–E235.
https://doi.org/10.1111/1469-0691.12142.
19. Poirel L, Castanheira M, Carrer A, Rodriguez CP, Jones RN, Smayevsky J,
Nordmann P. 2011. OXA-163, an OXA-48-related class D b-lactamase
with extended activity toward expanded-spectrum cephalosporins. Anti-
microb Agents Chemother 55:2546–2551. https://doi.org/10.1128/AAC
.00022-11.
20. Dortet L, Oueslati S, Jeannot K, Tande D, Naas T, Nordmann P. 2015.
Genetic and biochemical characterization of OXA-405, an OXA-48-type
extended-spectrum b-lactamase without significant carbapenemase ac-
tivity. Antimicrob Agents Chemother 59:3823–3828. https://doi.org/10
.1128/AAC.05058-14.
21. Mairi A, Pantel A, Sotto A, Lavigne JP, Touati A. 2018. OXA-48-like carba-
penemases producing Enterobacteriaceae in different niches. Eur J Clin
Microbiol Infect Dis 37:587–604. https://doi.org/10.1007/s10096-017
-3112-7.
22. Naas T, Oueslati S, Bonnin RA, Dabos ML, Zavala A, Dortet L, Retailleau P,
Iorga BI. 2017. b-lactamase database (BLDB): structure and function. J
Enzyme Inhib Med Chem 32:917–919. https://doi.org/10.1080/14756366
.2017.1344235.
23. Tacao M, Silva I, Henriques I. 2017. Culture-independent methods reveal
high diversity of OXA-48-like genes in water environments. J Water
Health 15:519–525. https://doi.org/10.2166/wh.2017.260.
24. Preston KE, Hitchcock SA, Aziz AY, Tine JA. 2014. The complete nucleotide
sequence of the multi-drug resistance-encoding IncL/M plasmid pACM1.
Plasmid 76:54–65. https://doi.org/10.1016/j.plasmid.2014.08.005.
25. Thomas VL, McReynolds AC, Shoichet BK. 2010. Structural bases for stabil-
ity-function tradeoffs in antibiotic resistance. J Mol Biol 396:47–59.
https://doi.org/10.1016/j.jmb.2009.11.005.
26. Mehta SC, Rice K, Palzkill T. 2015. Natural variants of the KPC-2 carbapene-
mase have evolved increased catalytic efficiency for ceftazidime hydroly-
sis at the cost of enzyme stability. PLoS Pathog 11:e1004949. https://doi
.org/10.1371/journal.ppat.1004949.
27. Baquero F, Negri MC, Morosini MI, Blazquez J. 1998. Selection of very
small differences in bacterial evolution. Int Microbiol 1:295–300.
28. Baquero F, Negri MC, Morosini MI, Blazquez J. 1998. Antibiotic-selective
environments. Clin Infect Dis 27 Suppl 1:S5–S11. https://doi.org/10.1086/
514916.
29. Baier F, Hong N, Yang G, Pabis A, Miton CM, Barrozo A, Carr PD, Kamerlin
SC, Jackson CJ, Tokuriki N. 2019. Cryptic genetic variation shapes the
adaptive evolutionary potential of enzymes. Elife 8:e40789. https://doi
.org/10.7554/eLife.40789.
30. Zheng J, Payne JL, Wagner A. 2019. Cryptic genetic variation accelerates
evolution by opening access to diverse adaptive peaks. Science
365:347–353. https://doi.org/10.1126/science.aax1837.
31. Socha RD, Chen J, Tokuriki N. 2019. The molecular mechanisms underly-
ing hidden phenotypic variation among metallo-b-lactamases. J Mol Biol
431:1172–1185. https://doi.org/10.1016/j.jmb.2019.01.041.
32. Oueslati S, Retailleau P, Marchini L, Berthault C, Dortet L, Bonnin RA, Iorga
BI, Naas T. 2020. Role of arginine 214 in the substrate specificity of OXA-
48. Antimicrob Agents Chemother 64:e02329-19. https://doi.org/10.1128/
AAC.02329-19.
33. Dabos L, Bogaerts P, Bonnin RA, Zavala A, Sacre P, Iorga BI, Huang DT,
Glupczynski Y, Naas T. 2018. Genetic and biochemical characterization of
OXA-519, a novel OXA-48-like b-lactamase. Antimicrob Agents Chemo-
ther 62:e00469-18. https://doi.org/10.1128/AAC.00469-18.
34. Lund BA, Thomassen AM, Carlsen TJO, Leiros HKS. 2017. Structure, activity
and thermostability investigations of OXA-163, OXA-181 and OXA-245
using biochemical analysis, crystal structures and differential scanning
calorimetry analysis. Acta Crystallogr F Struct Biol Commun 73:579–587.
https://doi.org/10.1107/S2053230X17013838.
35. Dabos L, Zavala A, Bonnin RA, Beckstein O, Retailleau P, Iorga BI, Naas T.
2020. Substrate specificity of OXA-48 after b5-b6 loop replacement. ACS
Infect Dis 6:1032–1043. https://doi.org/10.1021/acsinfecdis.9b00452.
36. De Luca F, Benvenuti M, Carboni F, Pozzi C, Rossolini GM, Mangani S,
Docquier JD. 2011. Evolution to carbapenem-hydrolyzing activity in non-
carbapenemase class D b-lactamase OXA-10 by rational protein design.
Proc Natl Acad Sci U S A 108:18424–18429. https://doi.org/10.1073/pnas
.1110530108.
37. Venditti C, Nisii C, Ballardini M, Meledandri M, Di Caro A. 2019. Identifica-
tion of L169P mutation in the X loop of KPC-3 after a short course of cef-
tazidime/avibactam. J Antimicrob Chemother 74:2466–2467. https://doi
.org/10.1093/jac/dkz201.
38. Stojanoski V, Chow DC, Hu L, Sankaran B, Gilbert HF, Prasad BV, Palzkill T.
2015. A triple mutant in the X-loop of TEM-1 b-lactamase changes the
substrate profile via a large conformational change and an altered gen-
eral base for catalysis. J Biol Chem 290:10382–10394. https://doi.org/10
.1074/jbc.M114.633438.
39. Levitt PS, Papp-Wallace KM, Taracila MA, Hujer AM, Winkler ML, Smith KM,
Xu Y, Harris ME, Bonomo RA. 2012. Exploring the role of a conserved class
A residue in the X-loop of KPC-2 b-lactamase: a mechanism for ceftazi-
dime hydrolysis. J Biol Chem 287:31783–31793. https://doi.org/10.1074/
jbc.M112.348540.
40. Baurin S, Vercheval L, Bouillenne F, Falzone C, Brans A, Jacquamet L,
Ferrer JL, Sauvage E, Dehareng D, Frere JM, Charlier P, Galleni M, Kerff F.
2009. Critical role of tryptophan 154 for the activity and stability of class
D b-lactamases. Biochemistry 48:11252–11263. https://doi.org/10.1021/
bi901548c.
41. Fournier D, Hocquet D, Dehecq B, Cholley P, Plesiat P. 2010. Detection of
a new extended-spectrum oxacillinase in Pseudomonas aeruginosa. J Anti-
microb Chemother 65:364–365. https://doi.org/10.1093/jac/dkp438.
42. Meziane-Cherif D, Bonnet R, Haouz A, Courvalin P. 2016. Structural
insights into the loss of penicillinase and the gain of ceftazidimase activ-
ities by OXA-145 b-lactamase in Pseudomonas aeruginosa. J Antimicrob
Chemother 71:395–402. https://doi.org/10.1093/jac/dkv375.
43. Yang G, Miton CM, Tokuriki N. 2020. A mechanistic view of enzyme evolu-
tion. Protein Sci 29:1724–1747. https://doi.org/10.1002/pro.3901.
44. de Visser JA, Rozen DE. 2006. Clonal interference and the periodic selection
of new beneficial mutations in Escherichia coli. Genetics 172:2093–2100.
https://doi.org/10.1534/genetics.105.052373.
45. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. 2017.
In vitro selection of meropenem resistance among ceftazidime-avibac-
tam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates
with variant KPC-3 carbapenemases. Antimicrob Agents Chemother 61:
e00079-17. https://doi.org/10.1128/AAC.00079-17.
46. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R,
Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 2017. Emergence of ceftazi-
dime-avibactam resistance due to plasmid-borne blaKPC-3 mutations dur-
ing treatment of carbapenem-resistant Klebsiella pneumoniae infections.
Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/
AAC.02097-16.
47. Yurtsev EA, Chao HX, Datta MS, Artemova T, Gore J. 2013. Bacterial cheat-
ing drives the population dynamics of cooperative antibiotic resistance
plasmids. Mol Syst Biol 9:683. https://doi.org/10.1038/msb.2013.39.
b-Lactamase Evolution under Sub-MIC Conditions
March/April 2021 Volume 6 Issue 2 e00108-21 msphere.asm.org 17
 on A








48. Ribeiro AR, Sures B, Schmidt TC. 2018. Cephalosporin antibiotics in the
aquatic environment: a critical review of occurrence, fate, ecotoxicity and
removal technologies. Environ Pollut 241:1153–1166. https://doi.org/10
.1016/j.envpol.2018.06.040.
49. Watkinson AJ, Murby EJ, Kolpin DW, Costanzo SD. 2009. The occurrence
of antibiotics in an urban watershed: from wastewater to drinking water.
Sci Total Environ 407:2711–2723. https://doi.org/10.1016/j.scitotenv.2008
.11.059.
50. Tacao M, Correia A, Henriques IS. 2015. Low prevalence of carbapenem-
resistant bacteria in river water: resistance is mostly related to intrinsic
mechanisms. Microb Drug Resist 21:497–506. https://doi.org/10.1089/
mdr.2015.0072.
51. Jensen PR, Hammer K. 1998. Artificial promoters for metabolic optimiza-
tion. Biotechnol Bioeng 58:191–195. https://doi.org/10.1002/(SICI)1097
-0290(19980420)58:2/3,191::AID-BIT11.3.0.CO;2-G.
52. Samuelsen Ø, Naseer U, Karah N, Lindemann PC, Kanestrom A, Leegaard
TM, Sundsfjord A. 2013. Identification of Enterobacteriaceae isolates with
OXA-48 and coproduction of OXA-181 and NDM-1 in Norway. J Antimi-
crob Chemother 68:1682–1685. https://doi.org/10.1093/jac/dkt058.
53. Thomason LC, Costantino N, Court DL. 2007. E. coli genome manipulation
by P1 transduction. Curr Protoc Mol Biol Chapter 1:Unit 1.17. https://doi
.org/10.1002/0471142727.mb0117s79.
54. Baba T, Mori H. 2008. The construction of systematic in-frame, single-
gene knockout mutant collection in Escherichia coli K-12. Methods Mol
Biol 416:171–181. https://doi.org/10.1007/978-1-59745-321-9_11.
55. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal
genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S
A 97:6640–6645. https://doi.org/10.1073/pnas.120163297.
56. R Core Team. 2018. R: a language and environment for statistical comput-
ing. R Foundation for Statistical Computing, Vienna, Austria.
57. Lund BA, Christopeit T, Guttormsen Y, Bayer A, Leiros HK. 2016. Screening
and design of inhibitor scaffolds for the antibiotic resistance oxacillinase-
48 (OXA-48) through surface plasmon resonance screening. J Med Chem
59:5542–5554. https://doi.org/10.1021/acs.jmedchem.6b00660.
58. Fröhlich C, Sørum V, Huber S, Samuelsen O, Berglund F, Kristiansson E,
Kotsakis SD, Marathe NP, Larsson DGJ, Leiros SH. 2020. Structural and bio-
chemical characterization of the environmental MBLs MYO-1, ECV-1 and
SHD-1. J Antimicrob Chemother 75:2554–2563. https://doi.org/10.1093/
jac/dkaa175.
59. Hirvonen VHA, Mulholland AJ, Spencer J, van der Kamp MW. 2020. Small
changes in hydration determine cephalosporinase activity of OXA-48
b-lactamases. ACS Catal 10:6188–6196. https://doi.org/10.1021/acscatal
.0c00596.
60. Akhter S, Lund BA, Ismael A, Langer M, Isaksson J, Christopeit T, Leiros HS,
Bayer A. 2018. A focused fragment library targeting the antibiotic
resistance enzyme - Oxacillinase-48: synthesis, structural evaluation and
inhibitor design. Eur J Med Chem 145:634–648. https://doi.org/10.1016/j
.ejmech.2017.12.085.
61. Stojanoski V, Chow DC, Fryszczyn B, Hu L, Nordmann P, Poirel L, Sankaran
B, Prasad BV, Palzkill T. 2015. Structural basis for different substrate profiles
of two closely related class D b-lactamases and their inhibition by halo-
gens. Biochemistry 54:3370–3380. https://doi.org/10.1021/acs.biochem
.5b00298.
62. Rubenstein AB, Blacklock K, Nguyen H, Case DA, Khare SD. 2018. System-
atic comparison of Amber and Rosetta energy functions for protein struc-
ture evaluation. J Chem Theory Comput 14:6015–6025. https://doi.org/10
.1021/acs.jctc.8b00303.
63. Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling
C. 2015. ff14SB: improving the accuracy of protein side chain and back-
bone parameters from ff99SB. J Chem Theory Comput 11:3696–3713.
https://doi.org/10.1021/acs.jctc.5b00255.
64. Grand SL, Götz AW, Walker RC. 2013. SPFP: speed without compromise: a
mixed precision model for GPU accelerated molecular dynamics simula-
tions. Computer Physics Communications 184:374–380. https://doi.org/
10.1016/j.cpc.2012.09.022.
65. Salomon-Ferrer R, Gotz AW, Poole D, Le Grand S, Walker RC. 2013. Routine
microsecond molecular dynamics simulations with AMBER on GPUs. 2.
Explicit solvent particle mesh Ewald. J Chem Theory Comput 9:3878–3888.
https://doi.org/10.1021/ct400314y.
66. Roe DR, Cheatham TE III. 2013. PTRAJ and CPPTRAJ: software for process-
ing and analysis of molecular dynamics trajectory data. J Chem Theory
Comput 9:3084–3095. https://doi.org/10.1021/ct400341p.
67. Kabsch W. 2010. XDS. Acta Crystallogr D Biol Crystallogr 66:125–132.
https://doi.org/10.1107/S0907444909047337.
68. Evans PR, Murshudov GN. 2013. How good are my data and what is the
resolution? Acta Crystallogr D Biol Crystallogr 69:1204–1214. https://doi
.org/10.1107/S0907444913000061.
69. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd
JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW,
Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart
PH. 2010. PHENIX: a comprehensive Python-based system for macromo-
lecular structure solution. Acta Crystallogr D Biol Crystallogr 66:213–221.
https://doi.org/10.1107/S0907444909052925.
70. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and develop-
ment of Coot. Acta Crystallogr D Biol Crystallogr 66:486–501. https://doi
.org/10.1107/S0907444910007493.
71. Kayikci M, Venkatakrishnan AJ, Scott-Brown J, Ravarani CNJ, Flock T, Babu
MM. 2018. Visualization and analysis of non-covalent contacts using the
Protein Contacts Atlas. Nat Struct Mol Biol 25:185–194. https://doi.org/10
.1038/s41594-017-0019-z.
Fröhlich et al.
March/April 2021 Volume 6 Issue 2 e00108-21 msphere.asm.org 18
 on A
pril 29, 2021 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
